Clinical trials: Acquired Ptosis, active
Acquired Blepharophimosis
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
- Trial name
- NCT06514612
- Testing
- STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
- Where
- 36 sites in Czechia, France and 7 more
- Volunteers
- 234 people
- Sponsor
- Santen SAS
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Acquired Ptosis
Upneeq vs. Lumify Ptosis
This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis.
- Trial name
- NCT07390578
- Testing
- Oxymetazoline 0.1% (Upneeq), Brimonidine 0.025% (Lumify)
- Volunteers
- 50 people
- Sponsor
- Duke University
Blepharoptosis
A Study in Chinese Patients With Acquired Blepharoptosis
This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.
- Trial name
- NCT06683651
- Testing
- STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800
- Where
- 23 sites in China
- Volunteers
- 180 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.